Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53 - PubMed (original) (raw)

Comparative Study

Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53

S J Ullrich et al. Proc Natl Acad Sci U S A. 1993.

Abstract

The product of the p53 gene suppresses cell growth and plays a critical role in suppressing development of human tumors. p53 protein binds DNA, activates transcription, and can be phosphorylated at N- and C-terminal sites. Previously, wild-type p53 was shown to be hyperphosphorylated compared to mutant p53 during p53-mediated growth arrest in vivo. Here we show that Ser-15 and Ser-9 in the N-terminal transactivation domain of wild-type human p53 are phosphorylated in vivo in cells derived from the human glioblastoma line T98G. In [Ile237]p53 and [Ala143]p53, two natural p53 mutants from human tumors that are defective for activation of transcription, phosphorylation at Ser-15 was reduced and phosphorylation at Ser-392 was increased compared to wild-type p53. No change was observed at Ser-9. [His273]p53, a third mutant, had a phosphorylation state similar to that of wild-type p53. We suggest that phosphorylation of Ser-15 may depend on the ability of p53 to adopt a wild-type conformation and may contribute to p53's ability to block cell growth.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Oncogene. 1990 Feb;5(2):207-18 - PubMed
    1. Biochem Soc Trans. 1992 May;20(2):239-42 - PubMed
    1. J Virol. 1980 Apr;34(1):213-24 - PubMed
    1. EMBO J. 1983;2(11):1993-9 - PubMed
    1. Mol Cell Biol. 1984 Sep;4(9):1689-94 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources